Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04247204
Other study ID # R.20.01.711
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 8, 2020
Est. completion date October 5, 2020

Study information

Verified date January 2020
Source Mansoura University
Contact Hatem Abu Hashim, MD. FRCOG.PhD
Phone +20502300002
Email hatem_ah@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A good quality embryo and receptive endometrium are important aspects in achieving optimal outcomes in assisted reproductive treatment (ART). Endometrial thickness is an important marker of uterine receptivity. A thin endometrium defined by an endometrial thickness ≤7mm was reported as a poor factor associated with significantly lower implantation and pregnancy rates as well as a higher risk of miscarriage.

Nowadays, platelet-rich plasma (PRP) intrauterine infusion is a promising approach for the treatment of refractory thin endometrium in patients undergoing frozen-thawed embryo transfer. This is based on its ability to stimulate proliferation and angiogenesis with a large number of growth factors and cytokines i.e. the endometrium becomes thicker, with higher vascularity. PRP is easily prepared from an autologous blood sample that eliminates the risk of immunological reactions and transmission infections at low cost.

Endometrial blood flow is another important marker reflective of uterine receptivity. Although publications are increasing concerning the efficacy of PRP intrauterine infusion on endometrial expansion and proliferation in frozen-thawed embryo transfer cycles, yet its angiogenetic effects have not been evaluated so far in either thin endometrium or normal endometrium thickness.

Our study aims to evaluate endometrial and sub-endometrial vasculature patterns before and after PRP infusion in frozen-thawed embryo transfer cycles with normal endometrium thickness.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date October 5, 2020
Est. primary completion date August 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- Subfertile women undergoing frozen-thawed embryo transfer with at least previously failed one ICSI cycle.

- Age between 20-35 years.

- Women with endometrium thickness between 8-14 mm on D15 of the frozen embryo transfer cycle

Exclusion Criteria:

- Women with a thin endometrium (= 7 mm) on day 15 of the cycle.

- Women with known hematological or immunological disorders

- Women with uncontrolled endocrine or other medical conditions, such as hyperprolactinemia or thyroid diseases.

- Women with uterine abnormalities e.g. Asherman syndrome, myomas, uterine septum, bicornuate uterus.

- Women who refuse to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Platelet-rich plasma intrauterine infusion
For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hatem AbuHashim

References & Publications (1)

Nandi A, Martins WP, Jayaprakasan K, Clewes JS, Campbell BK, Raine-Fenning NJ. Assessment of endometrial and subendometrial blood flow in women undergoing frozen embryo transfer cycles. Reprod Biomed Online. 2014 Mar;28(3):343-51. doi: 10.1016/j.rbmo.2013.11.004. Epub 2013 Nov 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Vascularization index of the endometrial region Vascularization index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis. Day 15 to 18 of the frozen embryo transfer cycle
Secondary Flow index of the endometrial region Flow index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis Day 15 to 18 of the frozen embryo transfer cycle
Secondary Vascularization flow index of the endometrial region Vascularization flow index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis Day 15 to 18 of the frozen embryo transfer cycle
Secondary Vascularization index of the sub-endometrial region Vascularization flow index of the sub-endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis Day 15 to 18 of the frozen embryo transfer cycle
Secondary Flow index of the sub-endometrial region Flow index of the sub-endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis Day 15 to 18 of the frozen embryo transfer cycle
Secondary Vascularization flow index of the sub-endometrial region Vascularization flow index of the sub-endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis Day 15 to 18 of the frozen embryo transfer cycle
See also
  Status Clinical Trial Phase
Completed NCT01668446 - Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles Phase 4
Terminated NCT04092829 - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer N/A
Withdrawn NCT04954196 - Benefit of Amlodipine in HRT Cycle for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index Phase 2
Completed NCT04758871 - Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles Phase 4
Completed NCT03740568 - Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes. N/A
Completed NCT04013438 - Luteal Phase Support During Frozen Embryo Transfer Cycle Phase 3
Recruiting NCT04371783 - A Randomized Trial Comparing the Live Birth Rate of Immediate Versus Delayed FET Following a Freeze-all Strategy N/A
Recruiting NCT03976544 - Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients Phase 4
Recruiting NCT04804020 - Natural Cycle vs. Modified Natural Cycle vs. Artificial Cycle Protocol for Endometrial Preparation. N/A
Completed NCT04837768 - Effect of Intramuscular Progesterone Supplementation on Clinical and Ongoing Pregnancy Rates in Patients With Low Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Frozen Cycles N/A
Terminated NCT05802303 - Estrogen (Gel)Transdermal vs Oral Estrogen for Endometrial Preparation N/A
Recruiting NCT05716139 - Natural Cycle vs Programmed Cycle Frozen Embryo Transfer N/A
Enrolling by invitation NCT04455191 - Comparison of Thawing Embryos in Advance and on the Day of Transfer on Pregnancy Outcomes in FET Cycle N/A
Completed NCT03660007 - Incidence of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer
Recruiting NCT06307184 - Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
Recruiting NCT05739019 - The Impact of Past Coronavirus Disease 19 (COVID-19) Infection on the Live Birth Rates of Frozen Embryo Transfer Cycles
Recruiting NCT06239376 - Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients N/A
Completed NCT01943812 - Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation Phase 4
Active, not recruiting NCT05555121 - Rescue Progesterone Supplementation During Frozen Embryo Transfer Phase 2
Withdrawn NCT05168865 - Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. Phase 4